Next Article in Journal
“You Do It without Their Knowledge.” Assessing Knowledge and Perception of Stealthing among College Students
Next Article in Special Issue
Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab
Previous Article in Journal
Voluntary or Forced: Different Effects of Personal and Social Norms on Urban Residents’ Environmental Protection Behavior
Previous Article in Special Issue
Health Literacy Environment of Breast and Cervical Cancer among Black African Women Globally: A Systematic Review Protocol of Mixed Methods
Article

Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience

1
Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
2
Department of Nursing, MacKay Memorial Hospital, Taipei 10449, Taiwan
3
Department of Obstetric & Gynecology, MacKay Memorial Hospital, Hsinchu Branch, Hsinchu 30071, Taiwan
4
Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taitung Branch, Taitung 95054, Taiwan
5
Department of General Education, MacKay Junior College of Medicine, Nursing and Management, New Taipei City 11260, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2020, 17(10), 3523; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph17103523
Received: 27 April 2020 / Revised: 13 May 2020 / Accepted: 14 May 2020 / Published: 18 May 2020
(This article belongs to the Special Issue Gynecological Cancer)
Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) stage, cell types, completeness of surgery, lymph nodes (LN) status, adjuvant chemotherapy regimens, survival status, progression-free survival (PFS), and overall survival (OS) of 192 patients diagnosed as having stage IIIA1–IVB EOC over January 2008–December 2017 were analyzed retrospectively. Of them, 100 (52.1%) patients had been debulked optimally. Of all cases, 64.1% and 10.9% demonstrated serous and clear-cell carcinoma. Moreover, the FIGO stage, surgery completeness, and LN status affected recurrence/persistence and mortality (all p < 0.001). Clear cell carcinoma led to shorter survival than serous carcinoma (p = 0.002). Adjuvant chemotherapy regimens were divided into five main groups according to previous clinical trials. However, choice of chemotherapy failed to demonstrate significant differences in patient outcomes. Similar results were found in the sub-analysis of optimally debulked cases, except that intraperitoneal chemotherapy could reduce mortality risk when compared with GOG-158 (p = 0.042). Notably, retroperitoneal LN dissection in all cases or optimally debulked cases reduced risks of recurrence/persistence and mortality, and prolonged PFS and OS significantly (all p < 0.05). Without optimal debulking, LN dissection led to little improvement in outcomes. Various modified chemotherapy regimens did not prolong PFS and OS or reduce recurrence/persistence and mortality risks. LN dissection is strongly recommended to improve the completeness of surgery and patient outcome. Clear cell type has a poorer outcome than serous type, which requires more aggressive treatment and follow-up. View Full-Text
Keywords: fallopian tubal cancer; chemotherapy; lymphadenectomy; ovarian cancer; peritoneal cancer fallopian tubal cancer; chemotherapy; lymphadenectomy; ovarian cancer; peritoneal cancer
Show Figures

Figure 1

MDPI and ACS Style

Chang, C.-H.; Kuo, H.-L.; Chen, T.-C.; Weng, C.-S.; Lim, L.; Huang, W.-C.; Chang, C.-L.; Su, T.-H.; Wang, K.-G.; Wang, K.-L.; Yang, Y.-C.; Chen, J.-R. Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience. Int. J. Environ. Res. Public Health 2020, 17, 3523. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph17103523

AMA Style

Chang C-H, Kuo H-L, Chen T-C, Weng C-S, Lim L, Huang W-C, Chang C-L, Su T-H, Wang K-G, Wang K-L, Yang Y-C, Chen J-R. Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience. International Journal of Environmental Research and Public Health. 2020; 17(10):3523. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph17103523

Chicago/Turabian Style

Chang, Chia-Hua, Hsiao-Li Kuo, Tzu-Chien Chen, Chia-Sui Weng, Ling Lim, Wan-Chun Huang, Chih-Long Chang, Tsung-Hsien Su, Kuo-Gon Wang, Kung-Liahng Wang, Yuh-Cheng Yang, and Jen-Ruei Chen. 2020. "Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience" International Journal of Environmental Research and Public Health 17, no. 10: 3523. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph17103523

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop